119 related articles for article (PubMed ID: 8655118)
21. Long-term results of conversion from existing to microemulsion formulation of cyclosporine.
Neumayer HH; Färber L; Budde K; Kohnen R; Maibücher A; Schuster A; Vollmar J; Waiser J; Luft FC
Transplant Proc; 1996 Aug; 28(4):2207-13. PubMed ID: 8769202
[No Abstract] [Full Text] [Related]
22. [Non-immunologic factor: immunosuppressive drug-induced nephrotoxicity].
Nakatani T; Asai T
Hinyokika Kiyo; 2002 Nov; 48(11):699-705. PubMed ID: 12512145
[TBL] [Abstract][Full Text] [Related]
23. Kidney transplant recipients and the incidence of adverse reactions to cyclosporin.
Tolou-Ghamari Z; Palizban AA
Saudi Med J; 2004 Oct; 25(10):1499-500. PubMed ID: 15494834
[No Abstract] [Full Text] [Related]
24. An open randomized parallel group study to compare Sandimmune Neoral with Sandimmune soft gelatin capsule in stable renal transplant patients.
Park K; Koh YB; Kwak JY; Kim SJ; Yoon YS; Kang CM; Kim YS
Transplant Proc; 1996 Jun; 28(3):1202-3. PubMed ID: 8658627
[No Abstract] [Full Text] [Related]
25. Kidney graft dysfunction after drug interaction between miocamycin and cyclosporin.
Treille S; Quoidbach A; Demol H; Juvenois A; Dehout F; Abramowicz D
Transpl Int; 1999; 12(2):157. PubMed ID: 10363601
[No Abstract] [Full Text] [Related]
26. Safety, tolerability, and pharmacokinetics of Sandimmun Neoral: conversion study in stable renal transplant recipients.
Tsang WK; Ho YW; Tong KL; Chan WH; Chan A
Transplant Proc; 1996 Jun; 28(3):1330-2. PubMed ID: 8658681
[No Abstract] [Full Text] [Related]
27. [Cyclosporin in transplantation management--especially after kidney transplantation].
Quellhorst E
Internist (Berl); 1996 Jan; 37(1):88-90. PubMed ID: 8837834
[No Abstract] [Full Text] [Related]
28. Experience with clinical use of Sandimmun Neoral in renal transplant patients.
Min ZL; Zhao M; Zhu YH; Qi J; Wang LM; Wang YW
Transplant Proc; 1996 Jun; 28(3):1356-7. PubMed ID: 8658692
[No Abstract] [Full Text] [Related]
29. A comparison of the effects of C2-cyclosporine and C0-tacrolimus on renal function and cardiovascular risk factors in kidney transplant recipients.
Kim SJ; Prasad GV; Huang M; Nash MM; Famure O; Park J; Thenganatt MA; Chowdhury N; Cole EH; Fenton SS; Cattran DC; Zaltzman JS; Cardella CJ
Transplantation; 2006 Oct; 82(7):924-30. PubMed ID: 17038908
[TBL] [Abstract][Full Text] [Related]
30. Cortical blindness secondary to cyclosporine after orthotopic heart transplantation: a case report and review of the literature.
Drachman BM; DeNofrio D; Acker MA; Galetta S; Loh E
J Heart Lung Transplant; 1996 Nov; 15(11):1158-64. PubMed ID: 8956125
[TBL] [Abstract][Full Text] [Related]
31. Cyclosporine as a cause of unilateral gynecomastia in renal transplant recipient.
Kumar A; Bansal V; Mehra S; Minz M; Sharma AK
J Assoc Physicians India; 1999 Jul; 47(7):746. PubMed ID: 10778606
[No Abstract] [Full Text] [Related]
32. [Renal lymphoma in a patient after kidney transplantation and cyclosporine therapy].
Drahy G; Dion E; Faucher C; Bellin MF
J Radiol; 1992 Nov; 73(11):629-31. PubMed ID: 1296001
[TBL] [Abstract][Full Text] [Related]
33. [Multiple sebaceous hyperplasia secondary to ciclosporin in a heart transplant patient].
Grillo E; Pérez-Gala S; Vano-Galván S; Jaén-Olasolo P
Med Clin (Barc); 2013 Jul; 141(2):e3. PubMed ID: 23664109
[No Abstract] [Full Text] [Related]
34. Plasma endothelin in cyclosporine A-treated renal transplant patients.
Grekas D; Bamichas G; Karamouzis M; Bacharaki D; Savidis N; Tourkantonis A
Transplant Proc; 1999 May; 31(3):1703-5. PubMed ID: 10331044
[No Abstract] [Full Text] [Related]
35. [Transient blindness after liver transplant].
Ortiz RM; Pérez BS; Suárez Muñoz MÁ; Aguilar JL; Santoyo JS
Cir Esp; 2012 Mar; 90(3):206-7. PubMed ID: 21419394
[No Abstract] [Full Text] [Related]
36. Cyclosporine-associated encephalopathy: a case report and literature review.
Chang SH; Lim CS; Low TS; Chong HT; Tan SY
Transplant Proc; 2001; 33(7-8):3700-1. PubMed ID: 11750577
[No Abstract] [Full Text] [Related]
37. [Perivascular hyalin substance and calcinosis of the gingiva after cyclosporin A therapy--a new finding].
Sharaf MN; Hofstädter F
Pathologe; 1992 Apr; 13(2):117-20. PubMed ID: 1376475
[No Abstract] [Full Text] [Related]
38. Economic evaluation of therapeutic drug monitoring services in renal transplant recipients treated with cyclosporine.
Lee KL; Peng YL; Chou JL; Lee KT; Chung HM
Transplant Proc; 2000 Nov; 32(7):1801-6. PubMed ID: 11119944
[No Abstract] [Full Text] [Related]
39. [Improving long-term graft survival by limiting nephrotoxicity of immunosuppressors and reducing vascular risk].
Hourmant M
Nephrol Ther; 2009 Dec; 5 Suppl 6():S353-4. PubMed ID: 20129444
[No Abstract] [Full Text] [Related]
40. Bone mass evolution after renal transplantation.
Goffin E; Devogelaer JP; Depresseux G; van Ypersele de Strihou C
Kidney Int; 2001 Apr; 59(4):1594-5. PubMed ID: 11260428
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
